BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35380226)

  • 1. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology.
    Vietti Violi N; Gnerre J; Law A; Hectors S; Bane O; Doucette J; Abboud G; Kim E; Schwartz M; Fiel MI; Taouli B
    Eur Radiol; 2022 Sep; 32(9):6493-6503. PubMed ID: 35380226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
    Ahmed AF; Samreen N; Grajo JR; Zendejas I; Sistrom CL; Collinsworth A; Esnakula A; Shah JL; Cabrera R; Geller BS; Toskich BB
    Abdom Radiol (NY); 2018 Jul; 43(7):1825-1836. PubMed ID: 29052747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes.
    King MJ; Tong A; Dane B; Huang C; Zhan C; Shanbhogue K
    Eur J Radiol; 2020 Dec; 133():109351. PubMed ID: 33096408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of hepatocellular carcinoma response to stereotactic body radiation using gadoxetate-enhanced MRI: A case series.
    Sharma HK; Kyriakakos C; Jabbour TE; Ward S; Buckstein M; Taouli B; Lewis S
    Eur J Radiol; 2023 Oct; 167():111077. PubMed ID: 37688918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy.
    Stocker D; King MJ; Homsi ME; Gnerre J; Marinelli B; Wurnig M; Schwartz M; Kim E; Taouli B
    Eur Radiol; 2024 Jan; 34(1):475-484. PubMed ID: 37540318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
    Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
    Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 10. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Yoon J; Lee S; Shin J; Kim SS; Kim GM; Won JY
    Korean J Radiol; 2021 Aug; 22(8):1279-1288. PubMed ID: 33987991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
    Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
    Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
    Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
    J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
    Pan J; Song M; Yang L; Zhao Y; Zhu Y; Wang M; Chen F
    Eur Radiol; 2023 Aug; 33(8):5801-5811. PubMed ID: 36894754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
    Byun J; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Hepatol Int; 2020 Jul; 14(4):534-543. PubMed ID: 32314171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
    Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Imaging Biomarkers for
    Schobert I; Chapiro J; Nezami N; Hamm CA; Gebauer B; Lin M; Pollak J; Saperstein L; Schlachter T; Savic LJ
    J Nucl Med; 2019 Aug; 60(8):1066-1072. PubMed ID: 30655331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma.
    Aujay G; Etchegaray C; Blanc JF; Lapuyade B; Papadopoulos P; Pey MA; Bordenave L; Trillaud H; Saut O; Pinaquy JB
    Diagn Interv Imaging; 2022; 103(7-8):360-366. PubMed ID: 35183483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.